New insider activity at Adaptive Biotechnologies ( (ADPT) ) has taken place on March 13, 2025.
In recent transactions involving Adaptive Biotechnologies stock, Sr. VP & Chief Medical Officer Robert Hershberg sold 53,000 shares, amounting to a total of $402,270. Additionally, Director Peter Neupert sold 10,000 shares, with the sale valued at $70,500.
Recent Updates on ADPT stock
Adaptive Biotechnologies has seen recent positive developments, particularly with the launch of an upgraded clonoSEQ assay for measurable residual disease detection, which has significantly increased sensitivity. The company reported strong financial performance in its recent earnings call, highlighting a 42% increase in MRD revenue and a robust cash position. Analysts have responded positively, with Piper Sandler raising the price target due to strong quarterly results and Scotiabank citing significant growth potential in the MRD business. Despite these achievements, challenges remain in the immune medicine segment, and the company has adopted a conservative outlook for MRD Pharma Services due to industry impacts. The strategic focus on expanding testing capabilities and leveraging partnerships is expected to drive future growth.
More about Adaptive Biotechnologies
YTD Price Performance: 21.00%
Average Trading Volume: 1,571,909
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.11B